These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1497392)

  • 1. Optimal therapeutic level of heparin therapy in patients with venous thrombosis.
    Hull RD; Raskob GE; Rosenbloom D; Lemaire J; Pineo GF; Baylis B; Ginsberg JS; Panju AA; Brill-Edwards P; Brant R
    Arch Intern Med; 1992 Aug; 152(8):1589-95. PubMed ID: 1497392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
    Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
    Hull R; Delmore T; Carter C; Hirsh J; Genton E; Gent M; Turpie G; McLaughlin D
    N Engl J Med; 1982 Jan; 306(4):189-94. PubMed ID: 7033782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
    Arch Intern Med; 1997 Nov; 157(20):2317-21. PubMed ID: 9361572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
    Elliott CG; Hiltunen SJ; Suchyta M; Hull RD; Raskob GE; Pineo GF; Jensen RL; Yeates S; Kitterman N
    Arch Intern Med; 1994 May; 154(9):999-1004. PubMed ID: 8179457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
    Anand S; Ginsberg JS; Kearon C; Gent M; Hirsh J
    Arch Intern Med; 1996 Aug 12-26; 156(15):1677-81. PubMed ID: 8694666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.
    Hull R; Delmore T; Genton E; Hirsh J; Gent M; Sackett D; McLoughlin D; Armstrong P
    N Engl J Med; 1979 Oct; 301(16):855-8. PubMed ID: 384248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different effects of heparin in males and females.
    Campbell NR; Hull RD; Brant R; Hogan DB; Pineo GF; Raskob GE
    Clin Invest Med; 1998 Apr; 21(2):71-8. PubMed ID: 9562927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
    Hull RD; Pineo GF
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
    Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
    Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.
    Hull RD; Raskob GE; Hirsh J; Jay RM; Leclerc JR; Geerts WH; Rosenbloom D; Sackett DL; Anderson C; Harrison L
    N Engl J Med; 1986 Oct; 315(18):1109-14. PubMed ID: 3531862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology and treatment of deep-vein thrombosis and pulmonary embolism.
    Carter BL; Jones ME; Waickman LA
    Clin Pharm; 1985; 4(3):279-96. PubMed ID: 3891200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
    Hull RD; Pineo GF; Stein P
    Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.
    Hull RD; Raskob GE; Rosenbloom D; Panju AA; Brill-Edwards P; Ginsberg JS; Hirsh J; Martin GJ; Green D
    N Engl J Med; 1990 May; 322(18):1260-4. PubMed ID: 2183055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
    Baker BA; Adelman MD; Smith PA; Osborn JC
    Arch Intern Med; 1997 Nov; 157(21):2475-9. PubMed ID: 9385299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.
    Levine MN; Hirsh J; Gent M; Turpie AG; Weitz J; Ginsberg J; Geerts W; LeClerc J; Neemeh J; Powers P
    Thromb Haemost; 1995 Aug; 74(2):606-11. PubMed ID: 8584992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin therapy in pediatric patients: a prospective cohort study.
    Andrew M; Marzinotto V; Massicotte P; Blanchette V; Ginsberg J; Brill-Edwards P; Burrows P; Benson L; Williams W; David M
    Pediatr Res; 1994 Jan; 35(1):78-83. PubMed ID: 8134203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.
    Hull R; Hirsh J; Jay R; Carter C; England C; Gent M; Turpie AG; McLoughlin D; Dodd P; Thomas M; Raskob G; Ockelford P
    N Engl J Med; 1982 Dec; 307(27):1676-81. PubMed ID: 6755255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.